User:Mr. Ibrahem/Fezolinetant

Mr. Ibrahem/Fezolinetant
Clinical data
Trade names	Veozah
Other names	ESN-364
License data	US DailyMed: Fezolinetant;
Routes of; administration	By mouth
Drug class	NK3 receptor blocker.
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name (4-fluorophenyl)-[(8R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone;
Chemical and physical data
Formula	C16H15FN6OS
Molar mass	358.40 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NS4)C;
	InChI InChI=1S/C16H15FN6OS/c1-9-13-19-20-14(15-18-10(2)21-25-15)23(13)8-7-22(9)16(24)11-3-5-12(17)6-4-11/h3-6,9H,7-8H2,1-2H3/t9-/m1/s1; Key:PPSNFPASKFYPMN-SECBINFHSA-N;

Fezolinetant, sold under the brand name Veozah, is a medication used to treat hot flashes due to menopause.^[2] Specifically it is used for moderate or severe symptoms.^[1] It is taken by mouth.^[1]

Common side effects include abdominal pain, diarrhea, trouble sleeping, back pain, and liver problems.^[1] Use is not recommended in those with significant kidney or liver problems.^[1] It is a neurokinin-3 (NK₃) receptor blocker.^[1]

Fezolinetant was approved for medical use in the United States in 2023.^[1] In the United States it costs about 560 USD per month as of 2023.^[3] The manufacturer applied for approval in Europe in 2022.^[4]

References edit

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Veozah- fezolinetant tablet, film coated". DailyMed. 19 May 2023. Archived from the original on 25 May 2023. Retrieved 24 May 2023.
^ ^a ^b "FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause". U.S. Food and Drug Administration (FDA) (Press release). 12 May 2023. Archived from the original on 13 May 2023. Retrieved 13 May 2023. This article incorporates text from this source, which is in the public domain.
^ "Fezolinetant". GoodRx. Retrieved 13 August 2023.
^ Inc, Astellas Pharma. "European Medicines Agency Accepts Astellas' Marketing Authorization Application for Fezolinetant". www.prnewswire.com. Archived from the original on 16 October 2022. Retrieved 13 August 2023. {{cite web}}: |last1= has generic name (help)

[PI2023-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Veozah- fezolinetant tablet, film coated". DailyMed. 19 May 2023. Archived from the original on 25 May 2023. Retrieved 24 May 2023.

[FDA2023-2] "FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause". U.S. Food and Drug Administration (FDA) (Press release). 12 May 2023. Archived from the original on 13 May 2023. Retrieved 13 May 2023. This article incorporates text from this source, which is in the public domain.

[3] "Fezolinetant". GoodRx. Retrieved 13 August 2023.

[4] Inc, Astellas Pharma. "European Medicines Agency Accepts Astellas' Marketing Authorization Application for Fezolinetant". www.prnewswire.com. Archived from the original on 16 October 2022. Retrieved 13 August 2023. {{cite web}}: |last1= has generic name (help)

[1]

[2]

[3]

[4]